HHS releases COVID-19 monoclonal antibody to treat uninsured, underinsured patients
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for outpatients at high risk for hospitalization, may be eligible for free replacement doses from the Department of Health and Human Services. HHS plans to make 60,000 doses of the product available to providers under the initiative. Anticipating depletion of the federal government’s supply, HHS last month transitioned to commercial distribution of the therapy.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…